St.SR's point deserves to be revisited.
post# 89772
What is Cotara worth if it is sold outright after the FDA replies with a P3 decision? Any estimates? I understand that the paved path would be partnering, but wouldn’t the proceeds of a Cotara sale coupled with the recent loan provide enough capital to at least give the impression that Peregrine could go it alone?
Firechief, corporalagarn, how would you evaluate the idea of selling Cotara to fund Bavituximab's PIII/PIV -- allowing PPHM to enter into the semi-dark of a full-blown, randomised, double-blind PIII/PIV with survival as the primary endpoint? Would you risk clinical failure to maximise your return on the other side of a successful clinical trial?
Could they sell it for enough to make going it alone possible?
News 
Market Data 
Discover 
